Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds - 2Data centers in space: Will 2027 really be the year AI goes to orbit?
- 3Step by step instructions to Analyze Senior Insurance Contracts Really.
- 4Bombardier Global 8000 Enters Service
- 5The Best Design Bloggers for Style Motivation
- Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- Israel faces widespread condemnation as NGO ban comes into effect
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Putin says Russian forces will seize capital of Zaporizhzhya
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- Web designers for Independent ventures
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- Scientists document a death from a meat allergy tied to certain ticks
